# Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

Study · id `cardio:ct-nct02539160` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02539160](<https://clinicaltrials.gov/study/NCT02539160>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02539160

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Coronary and vascular disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

## Technical summary

Registry record NCT02539160. Randomized; no masking; primary purpose treatment. Start 2016-02 (actual); primary completion 2019-11-14 (actual). Results posted on 2022-01-28.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 101 participants (enrolled count; ClinicalTrials.gov record NCT02539160, source copy `cardio:ctgov-nct02539160-2022-01-28`, retrieved 2026-10-26)
- Started: 2016-02 (actual) (ClinicalTrials.gov record NCT02539160, source copy `cardio:ctgov-nct02539160-2022-01-28`, retrieved 2026-10-26)
- Primary completion: 2019-11-14 (actual) (ClinicalTrials.gov record NCT02539160, source copy `cardio:ctgov-nct02539160-2022-01-28`, retrieved 2026-10-26)
- Completion: 2020-06-17 (actual) (ClinicalTrials.gov record NCT02539160, source copy `cardio:ctgov-nct02539160-2022-01-28`, retrieved 2026-10-26)
- Results first posted: 2022-01-28 (ClinicalTrials.gov record NCT02539160, source copy `cardio:ctgov-nct02539160-2022-01-28`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02539160, source copy `cardio:ctgov-nct02539160-2022-01-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02539160-2022-01-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
- Condition: Coronary Artery Disease
- Condition: Diabetes Mellitus
- Intervention (Drug): ticagrelor
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)

## Provenance

Content hash: e7e7d2b001b4648f9721e575ce76a285202979fb3765952f3504dd267264c4b4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
